A detailed history of Manufacturers Life Insurance Company, The transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Manufacturers Life Insurance Company, The holds 91,578 shares of SAGE stock, worth $972,558. This represents 0.0% of its overall portfolio holdings.

Number of Shares
91,578
Previous 55,701 64.41%
Holding current value
$972,558
Previous $1.21 Million 42.17%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$18.62 - $26.95 $668,029 - $966,885
35,877 Added 64.41%
91,578 $1.72 Million
Q4 2023

Feb 13, 2024

SELL
$17.1 - $22.26 $5.28 Million - $6.87 Million
-308,641 Reduced 84.71%
55,701 $1.21 Million
Q3 2023

Nov 15, 2023

SELL
$16.75 - $48.98 $3.85 Million - $11.2 Million
-229,596 Reduced 38.66%
364,342 $7.5 Million
Q2 2023

Aug 11, 2023

SELL
$40.65 - $59.54 $1.27 Million - $1.86 Million
-31,195 Reduced 4.99%
593,938 $27.9 Million
Q1 2023

May 15, 2023

SELL
$37.27 - $46.57 $17,218 - $21,515
-462 Reduced 0.07%
624,671 $26.2 Million
Q4 2022

Aug 11, 2023

SELL
$32.2 - $43.61 $24,117 - $32,663
-749 Reduced 0.12%
625,133 $23.8 Million
Q4 2022

Feb 13, 2023

SELL
$32.2 - $43.61 $24,117 - $32,663
-749 Reduced 0.12%
625,133 $23.8 Million
Q3 2022

Aug 11, 2023

SELL
$32.28 - $43.27 $33,764 - $45,260
-1,046 Reduced 0.17%
625,882 $24.5 Million
Q3 2022

Nov 03, 2022

SELL
$32.28 - $43.27 $33,764 - $45,260
-1,046 Reduced 0.17%
625,882 $24.5 Million
Q2 2022

Aug 11, 2023

SELL
$27.52 - $37.99 $2.14 Million - $2.96 Million
-77,891 Reduced 11.05%
626,928 $20.2 Million
Q2 2022

Aug 15, 2022

SELL
$27.52 - $37.99 $2.12 Million - $2.93 Million
-77,192 Reduced 10.96%
626,928 $20.3 Million
Q1 2022

Aug 11, 2023

BUY
$30.71 - $45.71 $2.46 Million - $3.66 Million
80,148 Added 12.83%
704,819 $23.3 Million
Q1 2022

May 20, 2022

BUY
$30.71 - $45.71 $11.3 Million - $16.9 Million
368,896 Added 110.04%
704,120 $23.4 Million
Q4 2021

Feb 16, 2022

SELL
$37.06 - $47.11 $2.08 Million - $2.65 Million
-56,257 Reduced 14.37%
335,224 $14.3 Million
Q3 2021

Nov 12, 2021

BUY
$40.26 - $57.37 $4.26 Million - $6.06 Million
105,694 Added 36.98%
391,481 $17.3 Million
Q2 2021

Aug 12, 2021

BUY
$54.88 - $79.29 $60,038 - $86,743
1,094 Added 0.38%
285,787 $16.2 Million
Q1 2021

May 03, 2021

BUY
$70.65 - $96.76 $1.9 Million - $2.6 Million
26,889 Added 10.43%
284,693 $21.3 Million
Q4 2020

Feb 12, 2021

SELL
$58.41 - $89.06 $3.26 Million - $4.96 Million
-55,741 Reduced 17.78%
257,804 $22.3 Million
Q3 2020

Nov 09, 2020

SELL
$41.13 - $62.45 $837,941 - $1.27 Million
-20,373 Reduced 6.1%
313,545 $19.2 Million
Q2 2020

Aug 10, 2020

BUY
$25.95 - $43.15 $1.99 Million - $3.31 Million
76,630 Added 29.78%
333,918 $13.9 Million
Q1 2020

May 15, 2020

BUY
$26.15 - $77.24 $143,354 - $423,429
5,482 Added 2.18%
257,288 $7.39 Million
Q4 2019

Feb 14, 2020

BUY
$60.18 - $154.77 $33,881 - $87,135
563 Added 0.22%
251,806 $18.2 Million
Q3 2019

Nov 12, 2019

SELL
$140.29 - $189.96 $425,078 - $575,578
-3,030 Reduced 1.19%
251,243 $35.9 Million
Q2 2019

Aug 14, 2019

BUY
$157.85 - $183.09 $5.19 Million - $6.02 Million
32,891 Added 14.86%
254,273 $46.6 Million
Q4 2018

Feb 14, 2019

BUY
$81.94 - $139.71 $1,884 - $3,213
23 Added 0.01%
221,382 $21.2 Million
Q3 2018

Nov 14, 2018

BUY
$138.11 - $169.04 $9.54 Million - $11.7 Million
69,046 Added 45.33%
221,359 $31.3 Million
Q2 2018

Aug 14, 2018

BUY
$140.36 - $175.76 $17 Million - $21.3 Million
121,246 Added 390.27%
152,313 $23.8 Million
Q1 2018

May 15, 2018

BUY
$152.15 - $192.33 $360,595 - $455,822
2,370 Added 8.26%
31,067 $5 Million
Q4 2017

Feb 08, 2018

BUY
$60.72 - $167.34 $129,394 - $356,601
2,131 Added 8.02%
28,697 $4.73 Million
Q3 2017

Nov 14, 2017

BUY
$61.4 - $88.52 $1.63 Million - $2.35 Million
26,566
26,566 $1.66 Million

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $631M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Manufacturers Life Insurance Company, The Portfolio

Follow Manufacturers Life Insurance Company, The and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Manufacturers Life Insurance Company, The, based on Form 13F filings with the SEC.

News

Stay updated on Manufacturers Life Insurance Company, The with notifications on news.